The Shaw Prize’s Post

Generalized myasthenia gravis (gMG) is a rare, chronic, autoantibody-driven neurological disease, and many people affected by gMG live with debilitating symptoms. Johnson & Johnson Innovative Medicine is committed to improving the lives of these patients through scientific innovation. We are proud to be presenting our latest research in gMG at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America, Inc. Scientific Session, which brings us one step closer to this goal. #rarediseases, #MyCompany, #AANEMinSavannah

📚 Exciting News! 📚 I am thrilled to share that our recent article titled "**Cerebral Venous Sinus Thrombosis as an Initial Presentation of Nephrotic Syndrome: A Case Report**" has been published in the esteemed Vascular Health and Risk Management journal. This case report sheds light on the rare but significant correlation between Nephrotic Syndrome and Cerebral Venous Sinus Thrombosis. This wouldn't have been possible without their relentless pursuit of knowledge and commitment to advancing the field of vascular health. Feel free to check out the article and share your thoughts. Let's continue the conversation and drive forward the frontiers of medical science together! #VascularHealth #RiskManagement #NephroticSyndrome #CerebralVenousSinusThrombosis #MedicalResearch

Explore Parkinson's disease pathogenesis in a new scientific journal article co-authored by Suruchi Bakshi , Certara's Principal Quantitative Systems Pharmacologist, alongside Govind Menon and J. Krishnan from Imperial College London.   Titled "The Interaction of Core Modules as a Basis for Elucidating Network Behavior Determining Parkinson's Disease Pathogenesis," this perspective paper introduces an approach based in dynamical systems theory to understanding the disease's intricate mechanisms.   Discover how the team combined key subnetwork interactions, focusing on alpha-synuclein's role in reactive oxygen species and proteasomal feedback pathways, to uncover emergent behaviors, potential treatment avenues, and broader implications for patient care and modeling strategies.   Read the full analysis and gain insights into systems medicine treatment options: https://ow.ly/Qj0w50QIK1G   #ParkinsonsResearch #Pathogenesis #TreatmentStrategies #SystemsMedicine #QSP #QuantiativeSystemsPharmacology

Thrilled to Share our Latest Publication ! I am excited to announce that our recent article, titled"The Role of Cobalamin in Multiple Sclerosis :An Update" has been published in the esteemed Journal of Inflammation. DOI: 10.1007/s10753-024-02075-6 #MultipleSclerosis,#Cobalamin

🆕Our September Paper of The Month is here: The Potential of GLP-1 Receptor Agonists in Stroke Prevention, a commentary by Prof. Dr. Octavio Marques Pontes-Neto: https://lnkd.in/dfHpHF8j 🧠💉GLP-1 receptor agonists, known for managing #diabetes and #obesity, show promise in reducing stroke risk by 16%. Could this be the next game-changer in #strokeprevention? 🔗Read the full analysis on the World Stroke Organization International Journal of Stroke (IJS) here, by Anastasia Adamou, Fotios Barkas, Haralampos Milionis and George Ntaios and dive into the potential of these therapies in addressing the #globalstrokeburden: https://lnkd.in/dCH8txBT #StrokePrevention #GLP1 #StrokeResearch #CardiovascularHealth #DiabetesCare #StrokeEducation

Learning about muscle today from Carla Prado, PhD, RD and David Evans, MD, FACS, FCCM, FASPEN! “1% of muscle loss results in a 5% increase in mortality and within 10 days patients can lose up to 20% of muscle.” This is why #NutritionMatters! #WhatRDsDo #ICUNutrition

Day 3 of #AAIC is here! To recap, here's a few pieces of our coverage of the meeting thus far: 📕 Education and Number of Household Members Negatively Impacts Cognitive Outcomes in Latino Individuals - https://lnkd.in/eytkbpJi 📗 Improvements in Alzheimer Apathy From Methylphenidate Not Driven by Cognitive Changes, ADMET 2 Data Show - https://lnkd.in/epdvA5KE 📙 Innovative Phase 2 Proof-of-Concept Trial to Test Effects of Benfotiamine as Alzheimer Treatment - https://lnkd.in/eUPpKXKx 📘 Alzheimer Agent T3D-959 Demonstrates Disease-Modifying Effects in Phase 2 PIONEER Trial - https://lnkd.in/ezqhNM8u

The manifestation of an immune response can result in #ocular inflammation impacting study duration, power, and the ability to meet objectives. Using immunosuppression can help mitigate inflammatory impact but may not completely quench the response. In this presentation, we explore the ethical and scientific considerations for using immunosuppression in non-clinical ocular studies and the benefits, concerns, and strategies for its use. https://okt.to/YZAgO1

Transverse myelitis is rare, yet dangerous, inflammatory process affecting a focal area of the spinal cord that may lead to rapid onset of irreversible paraplegia. This infographic nicely summarizes the pathogenesis, diagnosis, and treatment. Infographic from: Shah, The Infographic Guide To Medicine. #TransverseMyelitis #Paraplegia #PainMedicine

The manifestation of an immune response can result in #ocular inflammation impacting study duration, power, and the ability to meet objectives. Using immunosuppression can help mitigate inflammatory impact but may not completely quench the response. In this presentation, we explore the ethical and scientific considerations for using immunosuppression in non-clinical ocular studies and the benefits, concerns, and strategies for its use. https://okt.to/F9dkHy